-
Medtronic’s Kanghui Partners with Huashan Hospital to Create Neuroscience Innovation Platform
•
US major Medtronic, Inc.’s (NYSE: MDT) unit, Kanghui, has entered into a partnership with Huashan Hospital, affiliated with Fudan University in Shanghai, to establish the “Neuroscience Industry Research Medicine Integration Innovation Platform.” This collaboration aims to advance the field of neuroscience, particularly in the areas of cerebrovascular diseases, brain occupying…
-
JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report
•
JD Healthcare, a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD), has released its 2023 interim financial report, showing a 34% year-on-year (YOY) increase in total revenues to RMB 27.11 billion (USD 3.72 billion). Non-IFRS net profits surged by 101.2% to RMB 2.44 billion (USD 334.7 million), indicating strong financial…
-
Eisai’s Shanghai Unit Faces RMB 900,000 Penalty for Violating Drug Administration Law
•
Eisai Co., Ltd’s (TYO: 4523) Shanghai unit has been hit with an administrative penalty of RMB 900,000 (USD 124,000) by the Shanghai municipal market regulation administration bureau for violating Article 88 of the Drug Administration Law, as reported by “thepaper,” a local media outlet. Details of the Violation and Penalties…
-
Inmagene Biopharmaceuticals Initiates Global Study for IMG-007 in Atopic Dermatitis
•
China-based Inmagene Biopharmaceuticals has announced the first patient dosing in a global, multi-center, proof-of-concept study assessing the safety, pharmacokinetics, and efficacy of its pipeline candidate IMG-007. The molecule is being evaluated as a treatment for moderate-to-severe atopic dermatitis (AD), a condition that affects a significant patient population worldwide. IMG-007: An…
-
Sinovac Biotech Reports H1 2023 Financials with Significant Sales Decline from COVID-19 Boom
•
Sinovac Biotech Ltd (NASDAQ: SVA) has published its financial results for the first half of 2023, revealing a significant drop in sales from the COVID-19 surge experienced in the same period last year. Sales have fallen to USD 140.4 million, down from USD 1.2 billion in the first six months…
-
Gracell Biotechnologies Reports Q2 2023 Financials, Highlights GC012F in Melanoma Treatment
•
Suzhou-based biotech company Gracell Biotechnologies Inc., (NASDAQ: GRCL) has reported its financial results for the second quarter of 2023. The report highlights the company’s core product, GC012F, which has shown excellent data in multiple melanoma (MM) studies, as a key focus of their strategy moving forward. Clinical Trials and Development…
-
Legend Biotech Corporation Reports Q2 and H1 2023 Financials with Increased Revenues and R&D Spending
•
Legend Biotech Corporation (NASDAQ: LEGN) has released its financial results for the second quarter and the first half of 2023. For the three months ended June 30, 2023, the company reported license revenue of USD 15.1 million, attributed to the achievement of a milestone during the quarter. Collaboration revenue reached…
